Use of triterpensaponins, such as notoginsenoside R1 (NR1) and/or astragaloside (ASIV) for preparing medicaments

US5770578A · kind A · utility

Assignee

• Bergi GmbH · AT

Inventors

• Bernd Binder · Sersheim, DE
• Weijian Zhang · Wien, AT
• Johann Wojta · Wien, AT

Key dates

• Filing date: Jan 4, 1996
• Grant date: Jun 23, 1998
• Expiry date: Jan 4, 2016

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The use of triterpensaponins, like notoginsenoside R1 (NR1) and/or astragaloside (ASIV) for the production of medicaments for stimulating the fibrinolytic activity and blocking the endotoxin effect, especially for the treatment of patients and animals which suffer from endotoxin shock or to limit the endotoxin shock. Corresponding medicaments are also suitable prophylactive and therapeutic treatment of patients of coronary heart disease, peripheral arterial disease for patients who suffer from angina pectoris and for the prevention of such diseases in healthy persons.